Immunity against vaccine-preventable potentially neurotropic diseases in children treated for malignant brain tumours with HIT-91 chemo- and radiotherapy

European Journal of Cancer

Volumn 40, Issue 2, 2004, Pages 236-244

  Schuller, E ^a   Forster Waldl E ^a   Slavc, I ^a   Maurer, W ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Brain tumour; HIT 91 therapy; Neurotropic viruses; Vaccination; Vaccine preventable diseases; Waning immunity

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CISPLATIN; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VACCINE; LIVE VACCINE; LOMUSTINE; MEASLES VACCINE; METHOTREXATE; MUMPS VACCINE; VINCRISTINE; VIRUS VACCINE;

ADOLESCENT; ADULT; ANAMNESIS; ANTIBODY BLOOD LEVEL; ARTICLE; AUSTRIA; BRAIN CANCER; BRAIN DISEASE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GERMANY; HUMAN; HUMAN TISSUE; IMMUNOLOGY; LEUKOCYTE COUNT; MALE; MEASLES; MULTIMODALITY CANCER THERAPY; MUMPS; NERVE CELL LESION; NEUROTROPISM; PERCEPTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK FACTOR; SEROLOGY; STATISTICAL SIGNIFICANCE; TUMOR IMMUNITY; VACCINATION; VIRUS INFECTION;

EID: 0346023958     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.10.009     Document Type: Article

References (33)

1. Magnani C., Aareleid T., Viscomi S., Pastore G., Berrino F. Variation in survival of children with central nervous system malignancies diagnosed in Europe between 1978 and 1992. the EUROCARE study Eur. J. Cancer. 37:2000;711-721.
2. Roman D.D., Sperduto P.W. Neuropsychological effects of cranial radiation. current knowledge and future directions Int. J. Rad. Oncol. Biol. Phys. 31:1995;983-998.
3. Esolen L.M., Takahashi K., Johnson R.T. et al. Brain endothelial cell infection in children with acute fatal measles. J. Clin. Invest. 96:1995;2478-2481.
4. Measles prevention. recommendations of the immunization practices advisory committee (ACIP) MMWR. 38:1989;1-18.
5. Mumps prevention. recommendations of the immunization practices advisory committee (ACIP) MMWR. 38:1989;388-400.
6. Feldman S., Andrew M., Norris M., McIntyre B., Iyer R. Decline in rates of seropositivity for measles, mumps and rubella antibodies among previously immunized children treated for acute leukaemia. Clin. Infect. Dis. 27:1998;388-390.
7. Smith S., Schiffmann G., Karayalein G., Bonagura V. Immunodeficiency in long term survivers of acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster therapy. J. Pediatr. 127:1995;68-75.
8. Kortmann R.D., Kühl J., Timmermann B. et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood. results of the German prospective randomized trial HIT 91 Int. J. Radiat. Oncol. Biol. Phys. 46:2000;269-279.
9. Plotkin S.A. Immunologic correlates of protection induced by vaccination. Ped. Inf. Dis. 20:2001;63-75.
10. Holzmann H., Kundi M., Stiasny K. et al. Correlation between ELISA, hemagglutination inhibition and neutralization tests after vaccination against tick-borne encephalitis. J. Med. Virol. 48:1996;102-107.
11. Muller C., Zielinski C.C., Klepetko W., Knoflach P., Wolf H., Eibl M.M. Phenotypic and functional analysis of cellular cytotoxicity after splenectomy. Int. Arch. Allergy Appl. Immunol. 87:1988;76-80.
12. Packer J.R. Brain tumours in children. Arch. Neurol. 56:1999;421-425.
13. Ciofi degli Atti M, D'Argenio P, di Giorgio G, Grandori L, Filonzi A. Measles in Italy 2002: studies show correlation between vaccine coverage and incidence Eurosurveillance Weekly 2002, 6(49). http://www.eurosurveillance.org/ ew/2002/021205.asp .
14. Christenson B., Böttiger M. Measles antibody. comparison of long-term vaccination titers, early vaccination titers and naturally acquired immunity to and booster effects on the measles virus Vaccine. 12:1994;129-133.
15. Pabst H.F., Spady D.W., Carson M.M., Stelfox H.T., Beeler J.A., Krezolek M.P. Kinetics of immunologic responses after primary vaccination. Vaccine. 15:1997;10-14.
16. Anonymos Immunisation of the Immunocompromised Child. Best Practice Statement 2002. Royal College of Pediatrics and Child Health http://www.rcpch.ac.uk/publications/recent_publications/Immunocomp.pdf .
17. Tamashiro V.G., Perez H.H., Griffin D.E. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Ped. Inf. Dis. 6:1987;451-454.
18. McChesney M.B., Miller C.L., Rota P.A., Zhu Y.D., Antipa L., Lerche N.W. Experimental measles I. pathogenesis in the normal and the immunized host Virol. 233:1997;74.
19. Naniche D., Oldstone M.B.A. Generalized immunosuppression. how viruses undermine the immune response Cell. Mol. Life. Sci. 57:2000;1399-1407.
20. Hussey G.D., Goddard E.A., Hughes J. et al. The effect of Edmonston-Zagreb and Schwarz measles vaccination on immune response in infants. J. Inf. Dis. 173:1996;1320-1326.
21. Hirsch R.L., Mokhtarian F., Griffin D.E., Brooks B.R., Hess J., Johnson R.T. Measles virus vaccination of measles seropositive individuals suppress lymphocyte proliferation and chemotactic factor production. Clin. Immun. Immunp. 21:1981;341-350.
22. Markowitz L.E., Preblud S.R., Fine P.E.M., Orenstein W.A. Duration of live measles vaccine- induced immunity. J. Ped. Inf. Dis. 9:1990;101-110.
23. Feldman S., Gigliotti F., Bockhold C., Naegele R. Measles and rubella antibody status in previous vaccinated children with cancer. Med. Ped. Oncol. 16:1988;308-311.
24. Virusepidemiolog Information 2002, 9, 3-4. http://www.univie.ac.at/ virologie/seiten/index.htm.
25. Kaplan L.J., Daum S.D., Smaron M., McCarthy C.A. Severe measles in immunocompromised patients. JAMA. 267:1992;1237-1241.
26. Galazka A.M., Robertson S.E., Kraigher A. Mumps and mumps vaccine. a global review Bull. WHO. 77:1999;3-14.
27. Dwyer D.E., Hueston I., Field P.R., Cunningham A.L., North K. Acute encephalitis complicating rubella virus infection. Ped. Inf. Dis. J. 11:1992;238-240.
28. Weibel R.E., Villarejos V.M., Klein E.B., Buynak E.B., McLean A.A., Hilleman M.R. Clinical and laboratory studies of live attenuated RA 27/3 and HPV-77DE rubella virus vaccines. Proc. Soc. Exp. Biol. Med. 165:1980;44-49.
29. Christenson B., Bottiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine. 12:1994;41-45.
30. Hargrave D.R., Hann I.M., Richards S.M.et al. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukemia trials from 1980 to 1997 (UKALL VIII, X and XI). Br. J. Haematol. 112:2001;293-299.
31. Gray M.M., Hann I.M., Glass S., Eden O.B., Jones P.M., Stevens R.F. Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centres. a retrospective review Br. Med. J., Clin. Res. Ed. 295:1987;19-22.
32. Kernahan J., McQuillan J., Craft W.A. Measles in children who have malignant disease. Br. Med. J. 295:1987;15-18.
33. Hughes I., Jenney M.E.M., Newton R.W., Morris D.J., Klapper P.E. Measles encephalitis during immunosuppressive treatment for acute lymphoblastic leukaemia. Arch. Dis. Child. 68:1993;775-778.